Avidity Biosciences (RNA) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free RNA Stock Alerts $29.50 +0.78 (+2.72%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 11:43 PM | investing.comAvidity Biosciences Inc (RNA)May 19 at 1:14 PM | seekingalpha.comAvidity Biosciences: Strong Buy With Promising RNA Therapeutics PipelineMay 19 at 1:14 PM | finance.yahoo.comBank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ StocksMay 18 at 4:44 AM | americanbankingnews.comMichael F. Maclean Sells 75,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 17 at 11:22 AM | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $2,121,000.00 in StockMay 15, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings ResultsAvidity Biosciences (NASDAQ:RNA - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.02. The business had revenue of $3.54 million for the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had a negative return on equity of 37.98% and a negative net margin of 2,103.78%.May 15, 2024 | prnewswire.comAvidity Biosciences Announces Appointment of Simona Skerjanec to Board of DirectorsMay 14, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Sets New 52-Week High at $28.19Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month High at $28.19May 14, 2024 | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)May 14, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)May 13, 2024 | markets.businessinsider.comAvidity Biosciences: Strong Buy on Promising Trials and Solid FinancialsMay 12, 2024 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down to $27.10May 10, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Rating Reaffirmed by Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $33.00 price target on shares of Avidity Biosciences in a research note on Friday.May 10, 2024 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsMay 10, 2024 | investorplace.comRNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | seekingalpha.comAvidity Biosciences files automatic mixed shelfMay 9, 2024 | markets.businessinsider.comBuy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory AdvancementsMay 9, 2024 | prnewswire.comAvidity Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsMay 8, 2024 | markets.businessinsider.comAvidity Receives Breakthrough Therapy Designation For Its Myotonic Dystrophy Type 1 Drug CandidateMay 8, 2024 | msn.comAvidity gets FDA breakthrough therapy status for DM1 drugMay 8, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferenceMay 8, 2024 | finance.yahoo.comAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1May 8, 2024 | insidertrades.comSarah Boyce Sells 28,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockMay 7, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 28,000 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 28,000 shares of the firm's stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $25.54, for a total value of $715,120.00. Following the sale, the chief executive officer now directly owns 112,117 shares in the company, valued at approximately $2,863,468.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.May 4, 2024 | msn.comB of A Securities Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationMay 3, 2024 | markets.businessinsider.comNavigating 7 Analyst Ratings For Avidity BiosciencesMay 3, 2024 | seekingalpha.comBofA starts Avidity at buy, cites upcoming clinical dataMay 3, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Bank of AmericaBank of America began coverage on shares of Avidity Biosciences in a research note on Friday. They issued a "buy" rating and a $40.00 price objective for the company.April 30, 2024 | marketbeat.com129,414 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by abrdn plcabrdn plc bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 129,414 shares of the biotechnology company's stock, valued at approximately $1,171,000. abrdn plcApril 27, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Buy" from BrokeragesShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have been assigned a consensus rating of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target priceApril 23, 2024 | insidertrades.comArthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockApril 22, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 5,000 shares of the stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $22.82, for a total transaction of $114,100.00. Following the completion of the sale, the director now owns 14,830 shares of the company's stock, valued at approximately $338,420.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.April 22, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Up 6.5%Avidity Biosciences (NASDAQ:RNA) Trading 6.5% HigherApril 22, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $1.50 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Mirae Asset Global Investments Co. Ltd. grew its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 301.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 166,019 shares of the biotechnology company's stock afteApril 21, 2024 | marketbeat.comRaymond James & Associates Increases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Raymond James & Associates boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,921 shares of the biotechnologyApril 17, 2024 | marketbeat.comRaymond James Financial Services Advisors Inc. Raises Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 149.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,611 shApril 13, 2024 | msn.comUnveiling the key role of RNA modification in HIV-1 survival and replicationApril 13, 2024 | marketbeat.comVanguard Group Inc. Acquires 47,305 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Vanguard Group Inc. lifted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 1.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,014,490 shares of the biotechnology company's stocApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)April 8, 2024 | marketbeat.comSG Americas Securities LLC Invests $377,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)SG Americas Securities LLC bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 41,705 shares of the biotechnology company's stoApril 5, 2024 | insidertrades.comArthur A. Levin Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockApril 4, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 2.7% Following Insider SellingAvidity Biosciences (NASDAQ:RNA) Shares Down 2.7% on Insider SellingApril 4, 2024 | finance.yahoo.comInsider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 SharesApril 3, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 20,000 SharesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 20,000 shares of the business's stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $27.11, for a total value of $542,200.00. Following the sale, the director now directly owns 253,872 shares in the company, valued at $6,882,469.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.April 1, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $26.62Avidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $26.62March 27, 2024 | prnewswire.comAvidity Biosciences to Participate in Upcoming Investor ConferencesMarch 17, 2024 | finance.yahoo.comRNA Apr 2024 17.500 callMarch 16, 2024 | finance.yahoo.comRNA Apr 2024 17.500 putMarch 16, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $980,800.00 in StockMarch 16, 2024 | finance.yahoo.comRNA Apr 2024 22.500 call Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs RNA Media Mentions By Week RNA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.480.42▲Average Medical News Sentiment RNA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼123▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amicus Therapeutics News Today MorphoSys News Today TG Therapeutics News Today Maravai LifeSciences News Today Arrowhead Pharmaceuticals News Today Corcept Therapeutics News Today Merus News Today Bausch Health Companies News Today MoonLake Immunotherapeutics News Today Janux Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
